CyMedica Orthopedics launched a clinical trial to evaluate the effectiveness of the e-vive™ app-based muscle activation and patient engagement system for reducing pain and improving function in patients with knee osteoarthritis (OA).
The randomized, prospective trial will assess 120 OA patients, combining e-vive's data on muscle strength with data collected by commercially available wearables/smartwatch devices to gauge the effect of e-vive on an improvement in symptoms.
Cymedica received FDA 510(k) clearance for e-vive in 2017 as a data-driven muscle activation therapy and patient engagement tool for anterior cruciate ligament and total knee replacement (TKR) patients. The app works with embedded garment sensor technology to transmit data points (e.g. range of motion, activity levels, pain scores, etc.) directly to a secure cloud-based portal, allowing providers to track patient progress and patient-reported measures.
Earlier this year, results from a clinical trial of 66 TKR patients revealed that use of e-vive yielded statistically significant and positive results in patient rehabilitation.
Source: CyMedica Orthopedics, Inc.